top of page
An Industry Disruptor
Gut Microbiota derived and optimised signaling molecules that maintain immune tolerance (Nutraceuticals) but can also further direct a tailored immune function (Pharmaceuticals).
The Mechanism of Action for our therapeutics is via pattern recognition receptors on antigen presenting cells that polarise T cells with MHC class II molecules from Bifidobacterium spp. Upon presentation, our bioactives induce the tailored activation and proliferation of T cells that control the Th1/Th2 physiologic balance.
The Discovery Platform-iKAR
AI powered platform for the de novo design of microbiome derived signaling molecules
We integrate sequencing & informatics technologies with synthetic biology to identify and advance promising molecules
bottom of page